Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Investment Research | Jul 27, 2016 10:59PM ET
GlaxoSmithKline plc (NYSE:GSK) reported second-quarter 2016 core earnings of 70 cents per American Depositary Share (ADS), beating the Zacks Consensus Estimate of 55 cents.
Core earnings were also up 16% year over year at a constant exchange rate (CER). On the other hand, revenues grew 4% at CER to £6.5 billion driven by all of its business segments. The top line was primarily backed by sales growth of new pharmaceutical and vaccine products.
All growth rates mentioned below are on a year-on-year basis and at CER.
Quarterly Highlights
Glaxo reports results under three segments: Pharmaceuticals, Vaccines and Consumer Healthcare.
While revenues at the Pharmaceuticals and Consumer Healthcare segments were up 2% and 7%, respectively, the Vaccines segment witnessed an 11% surge.
New Pharmaceutical and Vaccine products – like Relvar/Breo Ellipta and Eperzan/Tanzeum among others – registered sales of £1.05 billion in the reported quarter. Glaxo expects these products to deliver at least £6 billion in annual revenues by 2018.
However, within Pharmaceuticals, sales were down 9% in International Pharmaceuticals. Sales in Emerging Markets (down 9%) were impacted by continued pressure on the Chinese business from healthcare reforms, which include significant price reductions and ongoing business restructuring at the company.
The segment also saw a 1% decline in U.S. sales, which was a result of generic competition for Avodart (down 36%) and dwindling sales of Relenza (down 97%) due to a reallocation of government funding. In Europe too, sales were down 7% mainly due to an 11% decline in Respiratory sales.
Sales of Glaxo’s respiratory drug Advair/Seretide continued to decline (13%) in the quarter.
Nevertheless, robust sales of Tivicay (£225 million) and Triumeq (£409 million) drove a 44% surged at the HIV segment in the reported quarter.
In the Consumer Healthcare division, sales witnessed an increase in the U.S. (9%), Europe (1%) and International markets (9%). Growth was primarily driven by contributions from the Wellness and Oral health brands such as Flonase OTC, Excedrin, Voltaren and Sensodyne.
Meanwhile, the Vaccines segment benefited from the continued uptake of newly acquired meningitis vaccine, Bexsero, from Novartis AG (NYSE:NVS) .
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.